Do you routinely integrate telomere length testing into the evaluation of patients with ILD?  

Not routinely unless the patient or caregiver have evidence of premature graying, liver cirrhosis, blood or marrow abnormalities. I would also consider it in rapidly deteriorating ILD or IPF. How this would affect my overall management is less algorithmic but more individually based.

"Routine" would be a stretch, but I have dramatically increased my utilization of telomere length testing with the publication of recent studies, including this one. I do not check telomere lengths in patients when I don't think it will impact my management, but there is uncertainty surrounding best...

I will apologize in advance, I don't have sources to my answer below. I loved this paper when it came through late last year! That said, I tend to do the same as detailed by Dr. Taskar. I wonder about several things in my day-to-day practice: Is the premature greying piece really the best thing t...